argenx SE

NasdaqGS:ARGX Stock Report

Market Cap: US$57.1b

argenx Dividends and Buybacks

Dividend criteria checks 0/6

argenx does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.6%

Buyback Yield

Total Shareholder Yield-0.6%
Future Dividend Yield0.03%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

argenx: Sights Set On $1,000

Nov 26

Argenx: The Magic May Be Already Priced In

Mar 24

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ARGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARGX's dividend payments have been increasing.


Dividend Yield vs Market

argenx Dividend Yield vs Market
How does ARGX dividend yield compare to the market?
SegmentDividend Yield
Company (ARGX)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Biotechs)2.3%
Analyst forecast (ARGX) (up to 3 years)0.03%

Notable Dividend: Unable to evaluate ARGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ARGX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ARGX has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/04 14:36
End of Day Share Price 2025/12/03 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 56 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
null nullBaird